Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Study to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes

Open-Label, Non-Randomized, Single-Arm, Multicenter Pilot Clinical Trial to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes

FAITH-T1D/1, exploratory, Phase I, open-label, non-randomized, single-arm, multicenter clinical trial designed to evaluate the dose-dependent effects of tirzepatide on gastric emptying in adults with type 1 diabetes (T1D) and overweight or obesity.

The study will investigate tirzepatide administered once weekly as an adjunct to participants' usual insulin therapy delivered through automated insulin delivery (AID) systems. Tirzepatide will be administered subcutaneously, with gradual dose escalation from 2.5 mg up to 15 mg at four-week intervals, according to clinical tolerability and the protocol-defined dosing schedule. Its use in this population is off-label.

The study follows a longitudinal, within-subject design in which each participant serves as their own control. Gastric emptying will be assessed by gastric emptying scintigraphy using a standardized solid meal at baseline and at weeks 4, 8, 16 and 24. The primary objective is to characterize changes in gastric emptying in relation to tirzepatide dose. Secondary and exploratory objectives include evaluating metabolic and glycemic parameters, gastrointestinal symptoms, postprandial glucagon, lipidomic and metabolomic profiles, and the safety and tolerability of treatment. Continuous glucose monitoring and AID system data will also be reviewed throughout the study.

The target is 12 evaluable participants, with a maximum of 14 participants allowed to account for early withdrawals before an evaluable post-baseline assessment. The study includes a screening period, approximately 24 weeks of treatment and follow-up assessments through week 30.

Safety assessments will include treatment-emergent adverse events, gastrointestinal symptoms, hypoglycemia and diabetic ketoacidosis, as well as monitoring of tolerability during dose escalation. An independent Data and Safety Monitoring Committee is planned in accordance with the protocol.

The trial will be conducted at two Spanish hospital centers: Hospital Universitario Ramón y Cajal and Hospital Universitari i Politècnic La Fe. The study is exploratory and mechanistic; it is intended to characterize pharmacodynamic effects, estimate within-subject changes and inform the design of future confirmatory studies, rather than establish definitive clinical efficacy.

Studieoversikt

Status

Rekruttering

Forhold

Intervensjon / Behandling

Studietype

Intervensjonell

Registrering (Antatt)

12

Fase

  • Fase 1

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • Madrid
      • Madrid, Madrid, Spania, 28034
        • Rekruttering
        • Hospital Universitario Ramón y Cajal
        • Ta kontakt med:

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Written informed consent: Participants must have received information about the study design, objectives, and potential risks and must provide written informed consent to participate.
  • Ability to comply with study procedures: Ability and willingness to understand the study, comply with the required procedures, and attend all scheduled visits.
  • Age and diagnosis: Age ≥18 years and an established diagnosis of type 1 diabetes mellitus (T1D) for at least 1 year.
  • Stable automated insulin delivery (AID) treatment: Stable treatment with an AID system for at least 90 days before the baseline visit (Visit 0), with a commitment to maintain the same mode of insulin delivery and insulin throughout the study.
  • Baseline HbA1c: HbA1c between 6.3% and 10.5% at baseline.
  • Body mass index and weight stability: BMI ≥25 kg/m², with stable body weight (variation ≤5 kg) during at least the 90 days before inclusion.
  • Contraception requirements: Participants with reproductive potential must agree to use effective contraception throughout the study and for at least 6 months after the end of the study. The protocol specifies a highly effective contraceptive method plus a barrier method for participants with reproductive potential.

Exclusion Criteria:

Glycemic control and diabetes

  1. Two or more episodes requiring hospitalization for poor glycemic control (hyperglycemia or diabetic ketoacidosis [DKA]) during the 180 days before the baseline visit.

  2. One or more episodes of severe hypoglycemia requiring assistance from another person during the 90 days before baseline.

    Diabetes complications

  3. Active proliferative diabetic retinopathy, or a history of ophthalmologic treatment (photocoagulation, intravitreal injections, or vitrectomy) during the previous 6 months, or anticipated need for such treatment during the 6 months after inclusion.

    Recent cardiovascular disease

  4. Cardiovascular events during the 60 days before baseline, including:

    • Acute myocardial infarction.
    • Stroke.
    • Coronary revascularization.
    • Hospitalization for unstable angina.
    • Heart failure. Gastrointestinal disorders and motility
  5. Clinically significant gastrointestinal disorders, including diabetic gastroparesis.

  6. Previous bariatric surgery.

  7. Chronic use of medications that directly affect gastrointestinal motilityRenal function

  8. Estimated glomerular filtration rate (eGFR) below 15 mL/min/1.73 m² at baseline.

    Neoplasms

  9. Active malignancy or malignancy in remission for less than 5 years.

  10. Personal or first-degree family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2).

    Psychiatric disorders

  11. Severe or unstable psychiatric disorders, including uncontrolled major depression, schizophrenia, bipolar disorder, or other severe psychiatric conditions, or severe mood or anxiety disorders during the previous 2 years.

    Concomitant medications

  12. Systemic glucocorticoid use for more than 14 days during the 90 days before baseline, excluding replacement therapy.

  13. Use of weight-loss medications or glucose-lowering medications other than insulin during the 90 days before baseline.

    Hypersensitivity

  14. Hypersensitivity to tirzepatide or any of its excipients.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Helsetjenesteforskning
  • Tildeling: N/A
  • Intervensjonsmodell: Enkeltgruppeoppdrag
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Tirzepatide

Tirzepatide with dose escalation from 2.5 mg to 15 mg.

Tirzepatide with dose escalation from 2.5 mg to 15 mg.

Hva måler studien?

Primære resultatmål

Resultatmål
Tidsramme
To characterize the dose-dependent effect of tirzepatide (2.5-15 mg) on gastric emptying (GE) in adults with type 1 diabetes (T1D) and overweight/obesity, assessed as the within-subject change from baseline using gastric emptying scintigraphy (GES).
Tidsramme: Baseline (Week 0) and Weeks 4, 8, 16, and 24.
Baseline (Week 0) and Weeks 4, 8, 16, and 24.

Sekundære resultatmål

Resultatmål
Tidsramme
Change from baseline in gastric emptying half-time (t½)
Tidsramme: Baseline (Week 0) and Weeks 4, 8, 16, and 24
Baseline (Week 0) and Weeks 4, 8, 16, and 24
Change from baseline in the area under the gastric retention curve over 0-4 hours (AUC₀-₄h).
Tidsramme: Baseline (Week 0) and Weeks 4, 8, 16, and 24
Baseline (Week 0) and Weeks 4, 8, 16, and 24
Change from baseline in gastric retention at 2 hours (%GR-2h).
Tidsramme: Baseline (Week 0) and Weeks 4, 8, 16, and 24
Baseline (Week 0) and Weeks 4, 8, 16, and 24
Change from baseline in gastric retention at 4 hours (%GR-4h).
Tidsramme: Baseline (Week 0) and Weeks 4, 8, 16, and 24
Baseline (Week 0) and Weeks 4, 8, 16, and 24
Changes in continuous glucose monitoring (CGM) metrics during tirzepatide dose escalation including time in tight range (70-140 mg/dL)
Tidsramme: During the 24-week treatment period, using CGM data from the final 7 days of each dose-titration phase
During the 24-week treatment period, using CGM data from the final 7 days of each dose-titration phase
Changes in continuous glucose monitoring (CGM) metrics during tirzepatide dose escalation including time in range (TIR, 70-180 mg/dL)
Tidsramme: During the 24-week treatment period, using CGM data from the final 7 days of each dose-titration phase
During the 24-week treatment period, using CGM data from the final 7 days of each dose-titration phase
Changes in continuous glucose monitoring (CGM) metrics during tirzepatide dose escalation including time in hypoglycemia
Tidsramme: During the 24-week treatment period, using CGM data from the final 7 days of each dose-titration phase
During the 24-week treatment period, using CGM data from the final 7 days of each dose-titration phase
Changes in continuous glucose monitoring (CGM) metrics during tirzepatide dose escalation including time in hyperglycemia
Tidsramme: During the 24-week treatment period, using CGM data from the final 7 days of each dose-titration phase
During the 24-week treatment period, using CGM data from the final 7 days of each dose-titration phase
Changes in continuous glucose monitoring (CGM) metrics during tirzepatide dose escalation including glycemic variability.
Tidsramme: During the 24-week treatment period, using CGM data from the final 7 days of each dose-titration phase
During the 24-week treatment period, using CGM data from the final 7 days of each dose-titration phase
Correlation between dose-dependent delays in gastric emptying and improvements in postprandial glucose excursions (TIR, 70-180 mg/dL).
Tidsramme: Baseline (Week 0) and Weeks 4, 8, 16, and 24; postprandial glucose assessed over the 6 hours following the standardized test meal
Baseline (Week 0) and Weeks 4, 8, 16, and 24; postprandial glucose assessed over the 6 hours following the standardized test meal
Changes in insulin requirements, including total daily insulin dose
Tidsramme: Baseline (Week 0) and during the 24-week treatment period, with assessments at Weeks 4, 8, 12, 16, 20, and 24.
Baseline (Week 0) and during the 24-week treatment period, with assessments at Weeks 4, 8, 12, 16, 20, and 24.
Changes in insulin requirements, including the ratio of prandial to basal insulin dose.
Tidsramme: Baseline (Week 0) and during the 24-week treatment period, with assessments at Weeks 4, 8, 12, 16, 20, and 24.
Baseline (Week 0) and during the 24-week treatment period, with assessments at Weeks 4, 8, 12, 16, 20, and 24.
Change in HbA1c from baseline to the end of the study.
Tidsramme: Baseline (Week 0) and Week 30 (end-of-study visit).
Baseline (Week 0) and Week 30 (end-of-study visit).
Changes in body weight (kg)
Tidsramme: Baseline (Week 0), Weeks 4, 8, 12, 16, 20, and 24, and Week 30 (end-of-study visit).
Baseline (Week 0), Weeks 4, 8, 12, 16, 20, and 24, and Week 30 (end-of-study visit).
Changes in body mass index (kg/m²)
Tidsramme: Baseline (Week 0), Weeks 4, 8, 12, 16, 20, and 24, and Week 30 (end-of-study visit).
Baseline (Week 0), Weeks 4, 8, 12, 16, 20, and 24, and Week 30 (end-of-study visit).
Changes in waist-to-hip ratio (cm)
Tidsramme: Baseline (Week 0), Weeks 4, 8, 12, 16, 20, and 24, and Week 30 (end-of-study visit).
Baseline (Week 0), Weeks 4, 8, 12, 16, 20, and 24, and Week 30 (end-of-study visit).
Changes in percentage of body fat
Tidsramme: Baseline (Week 0), Weeks 4, 8, 12, 16, 20, and 24, and Week 30 (end-of-study visit).
Baseline (Week 0), Weeks 4, 8, 12, 16, 20, and 24, and Week 30 (end-of-study visit).
Changes from baseline in postprandial glucagon concentrations
Tidsramme: Baseline (Week 0) and Weeks 4, 8, 16, and 24; blood samples collected at 0, 30, 60, 120, 180, and 240 minutes during each gastric emptying scintigraphy assessment
Baseline (Week 0) and Weeks 4, 8, 16, and 24; blood samples collected at 0, 30, 60, 120, 180, and 240 minutes during each gastric emptying scintigraphy assessment
Changes from baseline in postprandial lipidomic profiles (Lipoprotein Cholesterol (mg/dL))
Tidsramme: Baseline (Week 0) and Weeks 4, 8, 16, and 24; blood samples collected at 0, 30, 60, 120, 180, and 240 minutes during each gastric emptying scintigraphy assessment
Baseline (Week 0) and Weeks 4, 8, 16, and 24; blood samples collected at 0, 30, 60, 120, 180, and 240 minutes during each gastric emptying scintigraphy assessment
Changes from baseline in postprandial lipidomic profiles (Triglycerides (mg/dL))
Tidsramme: Baseline (Week 0) and Weeks 4, 8, 16, and 24; blood samples collected at 0, 30, 60, 120, 180, and 240 minutes during each gastric emptying scintigraphy assessment
Baseline (Week 0) and Weeks 4, 8, 16, and 24; blood samples collected at 0, 30, 60, 120, 180, and 240 minutes during each gastric emptying scintigraphy assessment
Changes from baseline in postprandial lipidomic profiles (Particle Number (nmol/L))
Tidsramme: Baseline (Week 0) and Weeks 4, 8, 16, and 24; blood samples collected at 0, 30, 60, 120, 180, and 240 minutes during each gastric emptying scintigraphy assessment
Baseline (Week 0) and Weeks 4, 8, 16, and 24; blood samples collected at 0, 30, 60, 120, 180, and 240 minutes during each gastric emptying scintigraphy assessment
Changes from baseline in postprandial lipidomic profiles (Particle Diameter (nm))
Tidsramme: Baseline (Week 0) and Weeks 4, 8, 16, and 24; blood samples collected at 0, 30, 60, 120, 180, and 240 minutes during each gastric emptying scintigraphy assessment
Baseline (Week 0) and Weeks 4, 8, 16, and 24; blood samples collected at 0, 30, 60, 120, 180, and 240 minutes during each gastric emptying scintigraphy assessment
Changes from baseline in postprandial metabolomic profiles (Glycoprotein (μmol/L))
Tidsramme: Baseline (Week 0) and Weeks 4, 8, 16, and 24; blood samples collected at 0, 30, 60, 120, 180, and 240 minutes during each gastric emptying scintigraphy assessment
Baseline (Week 0) and Weeks 4, 8, 16, and 24; blood samples collected at 0, 30, 60, 120, 180, and 240 minutes during each gastric emptying scintigraphy assessment
Changes from baseline in postprandial metabolomic profiles (LMWM (mmol/L))
Tidsramme: Baseline (Week 0) and Weeks 4, 8, 16, and 24; blood samples collected at 0, 30, 60, 120, 180, and 240 minutes during each gastric emptying scintigraphy assessment
Baseline (Week 0) and Weeks 4, 8, 16, and 24; blood samples collected at 0, 30, 60, 120, 180, and 240 minutes during each gastric emptying scintigraphy assessment
Incidence of treatment-emergent adverse events including gastrointestinal symptoms
Tidsramme: From the first dose of tirzepatide through the end-of-study visit (Week 30).
From the first dose of tirzepatide through the end-of-study visit (Week 30).
Incidence of treatment-emergent adverse events including hypoglycemia
Tidsramme: From the first dose of tirzepatide through the end-of-study visit (Week 30).
From the first dose of tirzepatide through the end-of-study visit (Week 30).
Incidence of treatment-emergent adverse events including diabetic ketoacidosis
Tidsramme: From the first dose of tirzepatide through the end-of-study visit (Week 30).
From the first dose of tirzepatide through the end-of-study visit (Week 30).
Tolerability of tirzepatide during dose escalation, assessed by the frequency of dose reductions
Tidsramme: During the 24-week treatment period, through Week 24
During the 24-week treatment period, through Week 24
Tolerability of tirzepatide during dose escalation, assessed by the proportion of participants unable to reach the target dose of 15 mg
Tidsramme: During the 24-week treatment period, through Week 24
During the 24-week treatment period, through Week 24

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

27. september 2026

Primær fullføring (Antatt)

1. oktober 2028

Studiet fullført (Antatt)

1. oktober 2028

Datoer for studieregistrering

Først innsendt

13. oktober 2026

Først innsendt som oppfylte QC-kriteriene

18. november 2026

Først lagt ut (Faktiske)

20. november 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

20. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

18. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

produkt produsert i og eksportert fra USA

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere